Abteilungsleiterin
Forschungsschwerpunkte
Risikoadaptierte Prostatakrebsfrüherkennung
Screening & Früherkennung
Klinische Epidemiologie
Medizinische Entscheidungsfindung
Wissenschaftliche Studien, Projekte
European Randomized Study of Screening for Prostate Cancer (ERSPC)
Organized Prostate cancer Testing (OPT) Sweden
PCBase Xtend Sweden
EU4Health PRAISE-U
EU EIC PATHFINDER PROMETHEUS
Prostate Cancer Foundation
Pro-Quant-AI
Salpingectomy for Prevention of Ovarian cancer Trial (SPOT)
NAKO Gesundheitsstudie (NAKO)
Weitere Aktivitäten und Mitgliedschaften
Adjunct Senior Lecturer, Department of Translational Medicine, Division of Urological Cancers, Lund University, Lund, Sweden
Geschäftsführung, Nationales Krebspräventionsentrum (NCPC), DKFZ
International Alliance for Cancer Early Detection (ACED) (Deputy Director für DKFZ)
Deutsches Konsortium für Translationale Krebsforschung (DKTK), DKFZ
Netzwerk Altersforschung (NAR), Direktorium
EU4Health PRAISE-U, Scientific Advisory Board Mitglied und Collaborator
American Cancer Society, Early detection of prostate cancer guideline panel Mitglied
American Urological Association/Society of Urologic Oncology (AUA/SUO) Early detection of prostate cancer guideline Mitglied
BJU International, Statistical editor
Wissenschaftliches Programmkommittee:
ICCP: 5th International Conference on Cancer Prevention (19-October 21, 2026): Overview · DKFZ Event Managment System (Indico)
EDx conference: The Early Detection of Cancer Conference – 6-8 October 2026, Edinburgh, UK
Aktuelle Doktoranden, Postdocs und Clinical Scientists
Neue:r PhD Student:in 2026
Ya Zhang
Dmitry Sergeev
Fabian Falkenbach
Caelan Haney
Publikationen
Ausgewählte Publikationen der letzten Jahre
Albers P, Carlsson S, Krilaviciute A, Seibold P, Becker N. The Proposed Introduction of a Prostate Cancer Screening Program in Germany: Procedure, Necessary Studies before Implementation, Benefits, and Risks. Dtsch Arztebl Int. 2026 May 29;123(11):arztebl.m2026.0040. doi: 10.3238/arztebl.m2026.0040.
Padhani AR, Carlsson S, Bratt O, Schoots IG. Introducing Key Performance Metrics for Assessing the Benefits and Harm of the Prostate Cancer Diagnostic Pathway. Eur Urol Oncol. 2026 Mar 17:S2588-9311(26)00061-1. doi: 10.1016/j.euo.2026.03.002.
Lin DW, Carlsson S, Filson CP, Kim SK, Kirkby E, Konety BR, Purysko AS, Souter LH. Updates to Early Detection of Prostate Cancer: AUA/SUO Guideline (2026). J Urol. 2026 May;215(5):491-501. doi: 10.1097/JU.0000000000004995.
Carlsson SV, Krilaviciute A, Al-Monajjed R, Seibold P, Kuczyk M, Gschwend JE, Debus J, Antoch G, Schimmöller L, Schlemmer HP, Kristiansen G, Kaaks R, Becker N, Albers P; PROBASE Study Group. Risk-adapted Prostate Cancer Screening Achieves Mammography-like Benefits: Evidence and Implications for Europe. Eur Urol. 2026 Mar;89(3):193-195. doi: 10.1016/j.eururo.2025.12.002.
Roobol MJ, de Vos II, Månsson M, Godtman RA, Talala KM, den Hond E, Nelen V, Villers A, Poinas G, Kwiatkowski M, Wyler S, Recker F, Puliti D, Gorini G, Zappa M, Paez A, Lujan M, Bangma CH, Tammela T, Schröder FH, Remmers S, Hugosson J, Auvinen A; ERSPC Investigators. European Study of Prostate Cancer Screening - 23-Year Follow-up. N Engl J Med. 2025 Oct 30;393(17):1669-1680. doi: 10.1056/NEJMoa2503223.
Vertosick EA, Vickers A, Dahlin A, Ulmert D, Carlsson SV, Eastham J, Bjartell A, Lilja H. Prostate-specific antigen levels at age 60 years and lifetime risk of lethal prostate cancer. J Natl Cancer Inst. 2025 Dec 1;117(12):2591-2597. doi: 10.1093/jnci/djaf271.
Garraway IP, Carlsson SV, Nyame YA, Vassy JL, Chilov M, Fleming M, Frencher SK, George DJ, Kibel AS, King SA, Kittles R, Mahal BA, Pettaway CA, Rebbeck T, Rose B, Vince R, Winn RA, Yamoah K, Oh WK. Prostate Cancer Foundation Screening Guidelines for Black Men in the United States. NEJM Evid. 2024 May;3(5):EVIDoa2300289. doi: 10.1056/EVIDoa2300289.
Josefsson A, Månsson M, Kohestani K, Spyratou V, Wallström J, Hellström M, Lilja H, Vickers A, Carlsson SV, Godtman R, Hugosson J. Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial. Eur Urol. 2024 Sep;86(3):223-229. doi: 10.1016/j.eururo.2024.04.037.
Bjerner J, Bratt O, Aas K, Albertsen PC, Fosså SD, Kvåle R, Lilja H, Müller C, Müller S, Stensvold A, Thomas O, Røe OD, Vickers A, Walz J, Carlsson SV, Oldenburg J. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium. Eur Urol. 2024 Jul;86(1):20-26. doi: 10.1016/j.eururo.2023.04.028.
Hugosson J, Månsson M, Wallström J, Axcrona U, Carlsson SV, Egevad L, Geterud K, Khatami A, Kohestani K, Pihl CG, Socratous A, Stranne J, Godtman RA, Hellström M; GÖTEBORG-2 Trial Investigators. Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only. N Engl J Med. 2022 Dec 8;387(23):2126-2137. doi: 10.1056/NEJMoa2209454.